Session » Antiphospholipid Syndrome Poster

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 156

Assessing the Role of Ascvd Score in Primary Thrombosis Prophylaxis Strategy Among Asymptomatic Antiphospholipid Antibody Carriers

9:00AM-11:00AM: Abstract Number: 165

Clinical and Immunological Features of Antiphospholipid Syndrome in the Elderly: A Retrospective National Multicenter Study

9:00AM-11:00AM: Abstract Number: 161

Clinical and Laboratory Characteristics of Persistently Antiphospholipid Antibody Positive Patients: Retrospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)

9:00AM-11:00AM: Abstract Number: 163

Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Item Reduction Survey

9:00AM-11:00AM: Abstract Number: 171

Flow Cytometric Assessment of the Mammalian Target of Rapamycin Pathway Using Antiphospholipid Syndrome As a Disease Model

9:00AM-11:00AM: Abstract Number: 157

Identifying Additional Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Unique Cohort of Antiphospholipid Antibody Positive Chinese Patients

9:00AM-11:00AM: Abstract Number: 168

IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients

9:00AM-11:00AM: Abstract Number: 158

Incidence and Prevalence of Antiphospholipid Syndrome in a Health Management Organization (HMO): A 15-Year Study

9:00AM-11:00AM: Abstract Number: 162

Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/racemosa

9:00AM-11:00AM: Abstract Number: 170

Predictive Value of Antiphospholipid Antibodies in the Acute Phase of Deep Vein Thrombosis

9:00AM-11:00AM: Abstract Number: 160

Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)

9:00AM-11:00AM: Abstract Number: 169

Prognosis of Patients with Antiphospholipid Syndrome Nephropathy

9:00AM-11:00AM: Abstract Number: 167

Recurrent Thrombosis in Patients with Antiphospholipid Antibodies Following an Initial Venous or Arterial Thromboembolic Event

9:00AM-11:00AM: Abstract Number: 164

Reliability of Lupus Anticoagulant and Anti-Phosphatidylserine/Prothrombin Autoantibodies in Antiphosphospholipid Syndrome: A Multicenter Study

9:00AM-11:00AM: Abstract Number: 174

Rivaroxaban Versus Warfarin As Secondary Thromboprophylaxis in Patients with Antiphospholipid Syndrome: A Randomized, Multicenter, Open-Label, Clinical Trial

9:00AM-11:00AM: Abstract Number: 172

Serum Chemokines and miRNA Levels and Its Association with Cumulative Organ Damage in Patients with Antiphospholipid Syndrome: A Bench to Bedside Study

9:00AM-11:00AM: Abstract Number: 166

Superior Sensitivity for Detection of Primary Antiphospholipid Syndrome By a 9-Test Panel in Patients with Deep Venous Thrombosis, Pulmonary Embolism, and Stroke or Transient Ischemic Attack

9:00AM-11:00AM: Abstract Number: 173

The Efficacy of Treatment with Low Dose Aspirin and Low Molecular Weight Heparin in Pregnant Women with Criteria Anti-Phospholipid Antibodies

9:00AM-11:00AM: Abstract Number: 159

The Frequency of Screening and Prevalence of Antiphospholipid Antibodies in the General Population

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].